Biotech

Benitec Biopharma (ASX:BLT, NASDAQ:BNTC, NASDAQ:BNTCW) received a total of $5,590,235 as a cash refund under an R&D tax credit.

Benitec Biopharma (ASX:BLT, NASDAQ:BNTC, NASDAQ:BNTCW) received a total of $5,590,235 as a cash refund under an R&D tax credit.
As quoted in the press release:

The refund relates to the costs of research and development which qualify as eligible R&D expenditure under the Federal Government’s Scheme. The funds will be used to advance Benitec’s human therapeutic programs in gene silencing.
About Benitec Biopharma Limited: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or ‘expressed RNAi’. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington’s Disease, chronic neuropathic pain and retinitis pigmentosa.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20748.58+216.40
TSXV724.19+9.53
DOW33212.96+575.77
S&P 5004158.24+100.40
NASD12131.13+390.48
ASX7182.70+76.80

COMMODITIES

Commodities
Gold1853.480.00
Silver22.120.00
Copper4.32+0.06
Palladium2076.570.00
Platinum957.080.00
Oil115.07+0.98
Heating Oil3.90+0.05
Natural Gas8.71-0.19

DOWNLOAD FREE REPORTS

×